Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1Since this is a Phase 1 trial focused on finding a safe dose rather than proving the treatment works, what does that mean for what we can realistically expect in terms of benefit versus risk for my child or young adult?
2. 2This trial involves injecting two viruses directly into the brain during surgery, followed by valacyclovir — can you walk me through what the surgical procedure would actually involve and what the most serious risks of this gene therapy approach could be?
3. 3The trial is specifically for patients whose brain tumor has come back and can be surgically removed — how would you assess whether surgery is a realistic option at this point, and are there standard treatments for recurrent disease we should consider first before looking at an experimental approach?
4. 4Since researchers are still measuring dose-limiting toxicity, meaning they're still figuring out how much of these viral agents is too much, how will my child be monitored during and after treatment, and what would trigger stopping the treatment if something goes wrong?
5. 5Given that one of the tumor types this trial targets is diffuse hemispheric glioma with an H3 G34 mutation, do we know whether my child's tumor has been tested for that specific mutation, and how does that affect whether this trial might even be worth pursuing?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.